دورية أكاديمية

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial

التفاصيل البيبلوغرافية
العنوان: Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
المؤلفون: Dytfeld, Dominik, Wróbel, Tomasz, Jamroziak, Krzysztof, Kubicki, Tadeusz, Robak, Paweł, Walter-Croneck, Adam, Czyż, Jarosław, Tyczyńska, Agata, Druzd-Sitek, Agnieszka, Giannopoulos, Krzysztof, Nowicki, Adam, Szczepaniak, Tomasz, Łojko-Dankowska, Anna, Matuszak, Magdalena, Gil, Lidia, Puła, Bartosz, Rybka, Justyna, Majcherek, Maciej, Usnarska-Zubkiewicz, Lidia, Szukalski, Łukasz, Końska, Agnieszka, Zaucha, Jan Maciej, Walewski, Jan, Mikulski, Damian, Czabak, Olga, Robak, Tadeusz, Lahoud, Oscar B, Zonder, Jeffrey A, Griffith, Kent, Stefka, Andrew, Major, Ajay, Derman, Benjamin A, Jakubowiak, Andrzej J *
المصدر: In The Lancet Oncology February 2023 24(2):139-150
قاعدة البيانات: ScienceDirect
الوصف
تدمد:14702045
DOI:10.1016/S1470-2045(22)00738-0